Advertisement
Advertisement

More Related Content

Similar to Economic analysis of Rift Valley fever prevention and control options from a multi-sectoral perspective in Kenya(20)

More from ILRI(20)

Advertisement

Recently uploaded(20)

Economic analysis of Rift Valley fever prevention and control options from a multi-sectoral perspective in Kenya

  1. Economic analysis of Rift Valley fever prevention and control options from a multi- sectoral perspective in Kenya T. Kimani1,4, E. Schelling2, M. Ngigi3, T. Randolph1 1 International Livestock Research Institute, Kenya 2 Swiss Tropical and Public Health Institute, Basel 3 Egerton University, Kenya 4 Food and Agriculture Organization of the United Nations, Kenya Presented at the 13th conference of the International Society of Veterinary Epidemiology and Economics (ISVEE), Maastricht, Netherlands, 20-24 August 2012
  2. Introduction: Rift Valley fever • Mosquito borne viral zoonosis, Africa and Middle East • Epizootics, every 3-15 years • Last two outbreaks in Eastern Africa: 1997-98, 2006-07 • Higher than normal rainfall, prolonged flooding, after a prolonged drought • Mosquito to animals • Infected animal and animal products to people • Impacts: economy wide • Livestock • Mortality; morbidity; trade bans, control costs • Public health • Mortality, morbidity and control costs 13th ISVEE- Maastricht, Netherlands
  3. Objective: CBA (livestock sector) and CEA (public health) of RVF control options, period: 2006-2015, assumed outbreak in 2014/2015 Approach: Step 3: Identification of Step 1: alternate prevention Transmission (SEIR) Model: strategies, simulation, by (poster 08.74, MSc, Fuhrimann ) farming systems, for high risk areas (20.2/65 million Livestock animals) demography Step 4: CBA & CEA: RVF impact •Mortality (RVF and other) Control •Milk loss (drought, mesures RVF(abortions and reductions),other abortions Step 2: •RVF Market effects, control Asses public health costs and costs, 2014/2015 DALYs DALYs of 2006/2007 RVF- •Pastoral system (MSc Thesis- A. Bitek) (13.5 m animals) 13th ISVEE- Maastricht, Netherlands
  4. Selected AH Strategies Based on current and past practices , involved technical consultations- closer to reality 1=Enhanced 1= Use of 1 =Pour-on insecticides for Inter-epidemic Surveillance insecticides for animal treatment vaccination schemes (+ vector) Larval 0= Baseline, 0 = none 0 = none Strategy 9 sentinel herds S1- Baseline 0 0 0 0 S2 1 1 1 1 S3 2 1 1 1 S4 0 1 0 1 S5 1 1 0 1 S6 2 1 0 1 S7 1 1 0 0 S8 2 0 0 0 S9 0 0 0 1 S10 0 1 1 1 S11 0 1 0 0 13th ISVEE- Maastricht, Netherlands
  5. Strategies • Vaccination Schemes • Baseline = 2008 – 2014, coverage 4-7% sheep and goats only, • Option 1 = 2 mass vaccinations 2012 (41-51%); 2013 (28- 33%); 4 species; ear tag & monitor 3 years • Option 2 = 1 mass vaccination 2012 (41-51%); annual vaccination of young animals only ( 6-11%); 4 species; ear tag • Enhanced surveillance from 2012, shorter reaction time (delay of 3 weeks from 6 weeks in 2007) • Larvicidal –limited application; reduce infection pressure by 7.5% • Pour-on treatments; 10% of susceptible animals (without ear tags); 3 applications; delay of 4 weeks; 6 weeks protection 13th ISVEE- Maastricht, Netherlands
  6. Results: Simulated Infected Proportions 0.250 Proportion infected 0.200 0.150 0.100 0.050 - Prevention and Control Strategy Cattle Sheep Goats Camels None of the evaluated measures and assumed levels of application would stop an RVF epidemic 13th ISVEE- Maastricht, Netherlands
  7. • 24 month Livestock producer losses-2006-07 US$ 225 Million RVF Milk loss Drought and 3% other abortions Drought and milk loss baseline 10% mortality 82% RVF Direct mortality 5% RVF Market effects ( US$ 9.3 million) RVF Outbreak containment (US$ 5.23million) 13th ISVEE- Maastricht, Netherlands
  8. Estimated RVF Impacts 2014/2015 90,000,000 80,000,000 70,000,000 60,000,000 Million US$ 50,000,000 40,000,000 30,000,000 20,000,000 10,000,000 - S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 Prevention and Control Strategy Losses Control costs 13th ISVEE- Maastricht, Netherlands
  9. Average annual impacts 2008 - 2015 60.00 50.00 40.00 Million US$ 30.00 20.00 10.00 - S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 Prevention and Control Strategy PV RVF losses PV other losses • 8 years:1 RVF outbreak, 3 droughts & 3 normal years • RVF impacts are relatively lower, • Likely to be overlooked in the on going resilience building livestock development activities 13th ISVEE- Maastricht, Netherlands
  10. Livestock sector: Incremental Benefits & Costs compared 7.00 6.00 5.00 US$ (Million) 4.00 3.00 2.00 1.00 - S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 Prevention and Control Strategy Incremental benefits (Saved losses) Incremental costs Strategy S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 BCR 2.2 3.3 0.4 2.0 3.2 3.7 5.2 1.5 1.0 - 13th ISVEE- Maastricht, Netherlands
  11. Public Health Costs and CEA -on going •4,035.6 DALYs estimated for 06/07 outbreak •Next step •Adjust DALYs for underreporting •Quantify the human RVF transmission from a known number of infected animals •Estimate costs/DALY Human RVF risk sources averted 13th ISVEE- Maastricht, Netherlands
  12. Additional analysis • The other two farming systems • Sensitivity analysis • Apply Social Accounting Matrix to estimate economy wide impacts of RVF under different control strategies 13th ISVEE- Maastricht, Netherlands
  13. Conclusions • This analysis more or less show that unless control measures are stepped up, the next RVF epizootic is likely to have devastating impacts. • The current baseline vaccination of 4-7% of small ruminants would barely have any impacts on reducing magnitude • Increasing vaccination coverage for all species would yield significant reductions in outbreak magnitude • RVF epidemics have significant impacts, but higher impacts are attributed to other causes. • Need for tools to address market level impacts e.g. food safety credibility and safe slaughter systems. 13th ISVEE- Maastricht, Netherlands
  14. Acknowledgements Funding from the International Development Research Centre (IDRC) via the Agriculture and Health Research Platform of CGIAR CDC Kenya and the Kenya Medical Research Institute Thank you for listening 13th ISVEE- Maastricht, Netherlands
Advertisement